Literature DB >> 12888905

Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia.

Eisuke Uehara1, Seisho Takeuchi, Taizo Tasaka, Yoshiko Matsuhashi, Yang Yang, Mitsuhiro Fujita, Takahiro Tamura, Masami Nagai, H Phillip Koeffler.   

Abstract

Methylation profile was analyzed in eleven cases of therapy-related leukemia (t-leukemia) for p14, p15, p16, Rb, hMLH1, hMSH2, MGMT, APC, RAR beta, DAPK, RIZ1, FHIT, and SOCS-1 genes by using methylation specific polymerase chain reaction (MSP) analysis. Six (55%) of eleven cases showed methylation of at least one gene. The average time to the development of t-leukemia after the treatment of the primary tumor was significantly shorter in patients with methylation than those without methylation (49.3 months vs. 133.2 months, P=0.044). These results suggest that hypermethylation might be involved in the development of t-leukemia.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12888905

Source DB:  PubMed          Journal:  Int J Oncol        ISSN： 1019-6439            Impact factor:   5.650


  6 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

2.  A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes.

Authors:  Anair Graciela Lema Fernandez; Barbara Crescenzi; Valentina Pierini; Valeria Di Battista; Gianluca Barba; Fabrizia Pellanera; Danika Di Giacomo; Giovanni Roti; Rocco Piazza; Emmalee R Adelman; Maria E Figueroa; Cristina Mecucci
Journal:  Leukemia       Date:  2019-03-28       Impact factor: 11.528

3.  Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Hiroshi Handa; Yoshiko Sasaki; Hikaru Hattori; Lobna Alkebsi; Tetsuhiro Kasamatsu; Takayuki Saitoh; Takeki Mitsui; Akihiko Yokohama; Norifumi Tsukamoto; Morio Matsumoto; Hirokazu Murakami
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

4.  Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia.

Authors:  Seisho Takeuchi; Masahide Matsushita; Martin Zimmermann; Takayuki Ikezoe; Naoki Komatsu; Taku Seriu; Martin Schrappe; Claus R Bartram; H Phillip Koeffler
Journal:  Leuk Res       Date:  2011-05-17       Impact factor: 3.156

5.  Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis.

Authors:  Eisuke Uehara; Seisho Takeuchi; Yang Yang; Tetsuya Fukumoto; Yoshiko Matsuhashi; Takahiro Tamura; Masahide Matsushita; Masami Nagai; H Phillip Koeffler; Taizo Tasaka
Journal:  Oncol Lett       Date:  2011-09-13       Impact factor: 2.967

6.  Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Authors:  Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.